Vis børsmeldingen
in combination with cytokines.
Cytokines are small proteins that are involved in cell signaling, and that are
very important in the immune system, modulating both cell-based and humoral
immune responses. The combination of cytokines with PCI Biotech’s vaccine
technology, fimaVacc, has been shown to be effective for enhancing cellular
immune responses that are important for the effect of therapeutic vaccines. The
now granted US patent gives broad coverage for the combination of various
cytokines with the fimaVacc technology.
There are many vaccines under development utilising cytokines to elicit immune
responses. The US patent granted today is important for PCI Biotech’s
development strategy, as it supplements our ability to generate an internal
future vaccine pipeline, in addition to bringing value for the fimaVacc
technology in partnering efforts, said Per Walday, CEO of PCI Biotech.
As part of PCI Biotech’s strategy for applying the PCI-technology for
therapeutic cancer vaccines, several global patent applications were filed in
2013 and 2014. Today’s granted US patent secure protection until 2035 and this
patent application is still pending in Europe and key Asian markets.
About fimaVacc
This novel vaccine technology applies a unique mode of action, triggered
endosomal release of antigens, to enhance the essential cytotoxic effect of
therapeutic cancer vaccines and works in synergy with several other state-of-
the-art vaccination technologies. The fimaVacc programme aims to enhance the
cellular immune responses that are important for the therapeutic effect of
vaccines, and the fimaVacc technology has proven excellent preclinical efficacy
with protein- and peptide-based vaccines. The technology has shown particularly
strong CD8 T-cell immune responses, which are important for therapeutic
vaccination, as well as enhanced helper (CD4) T-cell and antibody responses.
PCI Biotech successfully translated the vaccination technology into humans
through a Phase I study in healthy volunteers that was completed in May 2019.
The study covered more than 90 subjects and established the tolerability of
fimaVacc across a wide range of doses. The immune results provided proof-of-
concept and demonstrates fimaVacc’s potential to enhance overall T-cell
responses, by demonstrating improvement of the immunogenicity of vaccines in
healthy volunteers.
Effective induction of cytotoxic T-cells will be critical to realise the huge
potential of therapeutic cancer vaccines, but vaccines often fail to generate
such responses. Insufficient delivery of vaccine antigens to the appropriate
presentation pathway in the immune cells may be one of the main reasons for
weak cytotoxic T-cell responses. The fimaVacc technology has the potential to
effectively enhance vaccine presentation through these pathways.
Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
(mailto:pw@pcibiotech.no)Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Kilde
